Moderna Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Moderna Bundle
Unlock Strategic Clarity
Unlock the strategic potential of Moderna's product portfolio with our comprehensive BCG Matrix analysis. See at a glance which innovations are poised for explosive growth, which are reliably generating cash, and which may require a strategic re-evaluation.
This insightful preview highlights the key quadrants of Moderna's offerings, but the full BCG Matrix report provides the granular detail and actionable intelligence you need to make informed decisions.
Don't just guess where Moderna's future lies; know it. Purchase the full BCG Matrix to gain a clear roadmap for resource allocation, market penetration, and long-term competitive advantage.
This is your opportunity to gain a data-driven perspective on Moderna's market positioning. Equip yourself with the insights from the complete BCG Matrix and lead with confidence.
Ready to transform your understanding of Moderna's business? Invest in the full BCG Matrix for a complete strategic blueprint and immediate competitive clarity.
Stars
RSV Vaccine (mRESVIA, mRNA-1345)
Moderna's RSV vaccine, mRESVIA (mRNA-1345), received FDA approval in May 2024 for adults 60 and older, with European approval following in August 2024. By June 2025, its indications are set to expand to high-risk adults aged 18-59. This positions mRESVIA to capture a significant share of the rapidly growing RSV vaccine market, which is anticipated to reach $10.5 billion by 2030.
While facing competition from GSK and Pfizer, Moderna projects mRESVIA to be a substantial revenue contributor starting in 2025. The vaccine's innovative mRNA technology and convenient pre-filled syringe design provide distinct competitive advantages in this expanding therapeutic area.
Next-Generation COVID-19 Vaccine (mRNA-1283)
Moderna’s mRNA-1283, their next-generation COVID-19 vaccine, has a regulatory review deadline, known as a PDUFA goal date, set for May 31, 2025. This new vaccine is designed to meet changing consumer demands and offer better defense against the COVID-19 variants that are currently circulating.
The market for COVID-19 vaccines has generally stabilized, but there's a significant opportunity in updated and more effective versions. Moderna aims to capture a substantial portion of this high-growth segment with mRNA-1283. For instance, in 2023, Moderna reported total revenue of $6.1 billion, with their COVID-19 vaccine franchise being a major contributor, highlighting the ongoing financial significance of this product line.
Individualized Neoantigen Therapy (INT) (mRNA-4157/V940)
Individualized Neoantigen Therapy (INT), specifically mRNA-4157/V940, represents a significant advancement in personalized oncology, developed in partnership with Merck. This innovative treatment is currently undergoing rigorous Phase 3 clinical trials, targeting critical indications such as adjuvant melanoma and non-small cell lung cancer.
The oncology sector, especially personalized cancer therapies, is experiencing robust growth, driven by substantial unmet medical needs. The market for cancer immunotherapies alone was valued at approximately $150 billion in 2023 and is projected to reach over $200 billion by 2028, highlighting the immense potential for INT.
Positive outcomes from ongoing clinical trials and subsequent regulatory approvals, anticipated around 2027, could position mRNA-4157 as a frontrunner in a highly profitable and expanding therapeutic landscape. Successful market penetration would leverage Moderna's mRNA platform in a segment poised for continued expansion and innovation.
Seasonal Influenza Vaccine (mRNA-1010)
Moderna's standalone seasonal influenza vaccine, mRNA-1010, has shown promising results. In June 2025, Phase 3 trials revealed superior efficacy compared to existing licensed vaccines. This positions mRNA-1010 to potentially capture a substantial portion of the robust and consistent flu vaccine market, particularly among older adults. The global influenza vaccine market was valued at approximately $6.5 billion in 2023 and is projected to grow steadily.
- Market Potential: The flu vaccine market is a stable, multi-billion dollar industry offering consistent demand.
- Efficacy Advantage: mRNA-1010's demonstrated superiority in Phase 3 trials could lead to significant market penetration.
- Target Demographics: Older adults are a key demographic for flu vaccines, and mRNA-1010's improved efficacy is especially relevant here.
- Regulatory Pathway: Moderna is preparing for regulatory submissions, signaling a clear path to market entry.
CMV Vaccine (mRNA-1647)
Moderna's mRNA-1647, a Cytomegalovirus (CMV) vaccine, is currently advancing through Phase 3 clinical trials. Anticipated data readouts in 2025 will be crucial for assessing its efficacy and safety. This vaccine targets a significant unmet medical need, positioning it to potentially capture a substantial share of a high-growth market. Successful development could solidify Moderna's leadership in a novel vaccine category, significantly boosting future revenue.
- High Unmet Need: CMV infections cause significant morbidity and mortality, particularly in immunocompromised individuals and congenital cases, creating a substantial market opportunity.
- Phase 3 Progress: With Phase 3 trials underway and data expected in 2025, mRNA-1647 is nearing potential regulatory approval.
- First-in-Class Potential: A successful CMV vaccine would represent a first-in-class product for Moderna, establishing a new revenue stream and market leadership.
- Revenue Contribution: Commercialization could lead to billions in annual revenue, given the broad applicability and need for a CMV vaccine.
Future Growth: Pipeline of Vaccines and Therapies
Moderna's RSV vaccine, mRESVIA, gained FDA approval in May 2024 and is projected to be a significant revenue driver starting in 2025, targeting a market expected to reach $10.5 billion by 2030. Their next-generation COVID-19 vaccine, mRNA-1283, has a PDUFA goal date of May 31, 2025, aiming to capture a segment of the evolving COVID-19 vaccine market. The individualized neoantigen therapy (INT), mRNA-4157/V940, is in Phase 3 trials for melanoma and lung cancer, tapping into the oncology immunotherapies market valued at $150 billion in 2023. Additionally, the seasonal flu vaccine mRNA-1010 showed superior efficacy in Phase 3 trials in June 2025, poised to enter the $6.5 billion flu vaccine market. Finally, the CMV vaccine mRNA-1647 is in Phase 3 trials, with potential data readouts in 2025, addressing a significant unmet need in a high-growth vaccine category.
| Product | Status/Key Milestone | Target Market (2023/2025 Est.) | Projected Impact/Opportunity | Key Data Point |
| mRESVIA (RSV) | FDA Approved (May 2024), EU Approved (Aug 2024) | RSV Vaccine Market: $10.5B by 2030 | Significant revenue contributor from 2025 | Targeting adults 60+ and high-risk adults 18-59 |
| mRNA-1283 (COVID-19) | PDUFA Goal: May 31, 2025 | Evolving COVID-19 Vaccine Market | Capture share of updated vaccine segment | Designed for current variants |
| mRNA-4157/V940 (INT) | Phase 3 Trials (Melanoma, NSCLC) | Oncology Immunotherapies: $150B (2023) | Potential frontrunner in personalized oncology | Regulatory approvals anticipated around 2027 |
| mRNA-1010 (Influenza) | Phase 3 Superior Efficacy (June 2025) | Influenza Vaccine Market: $6.5B (2023) | Significant market penetration potential | Superior efficacy vs. licensed vaccines |
| mRNA-1647 (CMV) | Phase 3 Trials, Data Expected 2025 | High Unmet Need CMV Vaccine Market | Potential first-in-class product, billions in revenue | Addresses significant morbidity/mortality |
What is included in the product
Detailed Word Document
The Moderna BCG Matrix analyzes its product portfolio, categorizing vaccines and therapies into Stars, Cash Cows, Question Marks, and Dogs to guide investment and resource allocation.
Customizable Excel Spreadsheet
The Moderna BCG Matrix provides a clear, one-page overview, quickly clarifying the strategic positioning of each business unit to ease decision-making.
Cash Cows
Spikevax (COVID-19 Vaccine, mRNA-1273)
Spikevax, Moderna's pioneering mRNA COVID-19 vaccine, continues to be a significant revenue generator. In the first quarter of 2025, it brought in $84 million in sales. For the entirety of 2024, Spikevax achieved $3.1 billion in sales.
Although these figures represent a notable decrease from the peak sales experienced during the height of the pandemic, Spikevax remains a vital income stream. The market for COVID-19 vaccines has matured, shifting towards an endemic model where demand is more stable but lower.
Moderna is strategically repositioning its business to thrive in this endemic environment. The company's focus is on capitalizing on consistent seasonal demand for vaccinations and preserving its robust market share within this established vaccine category.
Established International COVID-19 Vaccine Sales
Moderna's established international COVID-19 vaccine sales represent a significant cash cow. Beyond its strong U.S. presence, the company actively pursues and secures international sales for Spikevax, demonstrating a global reach.
Participation in EU tender opportunities highlights Moderna's strategy to maintain a foothold in the evolving COVID vaccine market. These ongoing international agreements and tender wins are crucial for generating stable cash flow.
While the market has shifted from emergency response to endemic demand, these sales provide a predictable revenue stream. This consistent performance solidifies the international Spikevax business as a key contributor to Moderna's financial stability.
Existing Manufacturing and Supply Chain Infrastructure
Moderna's significant investment in its mRNA manufacturing and supply chain infrastructure has created a formidable asset. This robust network, initially developed to support the massive scale-up of Spikevax, now forms a reliable foundation for launching future mRNA products.
The efficiency gained from this established infrastructure translates into lower marginal costs for producing new mRNA vaccines. This operational advantage positions these manufacturing capabilities as a true 'cash cow,' generating consistent value through optimized production.
By leveraging these existing assets, Moderna can efficiently bring new vaccines to market, capitalizing on its prior investments. This ability to reuse and scale existing infrastructure is a key driver of its operational profitability and competitive edge.
Strategic Partnerships and Collaborations
Moderna leverages strategic partnerships to solidify its position, turning collaborations into reliable revenue generators. For instance, its alliance with Merck for an oncology candidate, such as the investigational mRNA-4157/V940, exemplifies this. This partnership not only shares the significant financial burden of drug development but also taps into Merck's established market presence, ensuring a smoother path to potential commercialization and consistent milestone payments.
These established collaborations act as Moderna's cash cows within the BCG matrix. They provide a steady, predictable income stream stemming from shared development successes and profit-sharing agreements. This financial stability is crucial, as it allows Moderna to fund its more ambitious, higher-risk ventures without jeopardizing its core operations.
The success of these partnerships is directly tied to the proven efficacy of Moderna's mRNA platform. This underlying technology acts as a powerful asset, attracting further collaboration opportunities and reinforcing the value proposition for existing partners. The consistent revenue from these ventures reduces the need for extensive internal cash outlays, freeing up capital for innovation.
- Merck Partnership: Focuses on oncology, exemplified by mRNA-4157/V940, generating milestone payments and shared profits.
- Revenue Stability: Partnerships provide consistent, low-risk revenue streams crucial for funding ongoing R&D.
- Market Access: Collaborations leverage partners' established market presence for broader reach.
- Financial Efficiency: Shared development costs and profits optimize internal cash utilization.
Intellectual Property and Platform Technology
Moderna's core mRNA technology and its robust intellectual property (IP) portfolio are significant assets, functioning as a powerful cash cow. This foundational platform, honed through the development of its COVID-19 vaccine, Spikevax, offers broad applicability across numerous therapeutic areas. The company holds a substantial number of patents protecting its mRNA constructs, delivery systems, and manufacturing processes, creating a formidable barrier to entry for competitors.
This extensive IP not only fuels future product development but also generates value through potential licensing agreements. For instance, Moderna has already engaged in partnerships that leverage its platform technology, indicating its revenue-generating potential beyond its own pipeline. The ongoing refinement and expansion of this IP portfolio are crucial for maintaining its competitive edge and ensuring continued value creation.
- Intellectual Property Protection: Moderna's extensive patent portfolio covers key aspects of its mRNA technology, safeguarding its innovation.
- Licensing Opportunities: The platform's broad applicability creates avenues for lucrative licensing deals with other pharmaceutical companies.
- Competitive Advantage: The patented mRNA technology provides a significant and defensible moat against direct competition.
- Future Revenue Streams: The IP acts as a foundation for developing a diverse range of future therapeutics and vaccines, ensuring long-term value.
Moderna's Spikevax: A Global Revenue Powerhouse
Moderna's established international COVID-19 vaccine sales, particularly Spikevax, represent a core cash cow. These sales provide a predictable revenue stream in an evolving endemic market, with international agreements and tender wins crucial for consistent cash flow. The company's strategic focus on seasonal demand and market share preservation in this category solidifies its financial stability.
What You’re Viewing Is Included
Moderna BCG Matrix
The BCG Matrix report you are currently previewing is the precise, unwatermarked, and fully formatted document you will receive immediately after completing your purchase. This means you can confidently assess the strategic insights and professional presentation of this essential business tool, knowing the final version will be identical and ready for immediate application in your planning or analysis.
Dogs
Endemic Human Coronaviruses Vaccine (mRNA-1287)
Moderna's Endemic Human Coronaviruses Vaccine (mRNA-1287) program, a preclinical initiative, was unfortunately discontinued in September 2024. This move places it firmly in the Dogs quadrant of the BCG Matrix. Its market share is effectively zero, as it never progressed beyond preclinical stages, and the decision to halt development signals a low perceived growth potential.
The discontinuation of mRNA-1287 suggests it was not projected to deliver substantial returns or capture significant market share. This strategic pivot allows Moderna to reallocate resources toward pipeline candidates exhibiting higher promise and greater potential for future commercial success.
RSV Vaccine for Infants (mRNA-1345 in infants)
Moderna's mRNA-1345 vaccine for infants, targeting Respiratory Syncytial Virus (RSV), has seen its development deprioritized. Emerging clinical data by September 2024 suggests it will not proceed beyond Phase 1 trials.
This decision points to a projected low market share and diminished growth prospects for mRNA-1345 in the infant segment. The company's strategic shift involves redirecting investment away from this specific indication.
Moderna is instead concentrating its RSV research and development efforts on more promising applications, likely those with more favorable early clinical outcomes or clearer commercial pathways, as of mid-2024.
KRAS Antigen-Specific Therapy (mRNA-5671)
KRAS Antigen-Specific Therapy (mRNA-5671) was a promising oncology candidate for Moderna, but its development was halted in September 2024. This discontinuation places it firmly in the 'cash trap' category of the BCG Matrix.
As a Phase 1 candidate, mRNA-5671 had a very low market share. The decision to cease further development indicates a recognition of low growth potential, likely stemming from insufficient clinical data or a strategic shift in Moderna's pipeline priorities.
The resources invested in mRNA-5671 were deemed not to warrant further expenditure, essentially becoming a cash trap. This means the program consumed capital without a clear or viable path to commercial success, impacting the allocation of funds for other, potentially more fruitful, ventures.
Triplet Oncology Candidate (mRNA-2752)
Moderna's oncology candidate, mRNA-2752, has been moved to the Dogs category of the BCG Matrix. As of September 2024, the company announced it will not advance this mRNA-based cancer vaccine beyond Phase 1 trials. This decision stems from emerging clinical data indicating limited efficacy.
The deprioritization of mRNA-2752 reflects its low market share and the assessment of low growth prospects, making it an unviable investment for continued development.
This strategic shift allows for the reallocation of resources to other oncology programs with greater potential. For instance, Moderna's focus remains on advancing its mRNA-based personalized cancer vaccines, with several candidates in mid-stage clinical trials, aiming for improved patient outcomes and market penetration in the burgeoning oncology sector.
- Program: Triplet Oncology Candidate (mRNA-2752)
- Status: Deprioritized, ceasing development beyond Phase 1 as of September 2024.
- Reasoning: Emerging clinical data indicated low growth prospects and viability.
- Strategic Implication: Resources reallocated to more promising oncology programs.
Congestive Heart Failure Candidate (mRNA-0184)
Moderna's mRNA-0184, a candidate for congestive heart failure, was discontinued in September 2024. This decision places it firmly in the 'Dogs' category of the BCG matrix.
With its discontinuation, mRNA-0184 had effectively zero market share. This low market penetration, coupled with the program's termination, signals very low growth potential.
The strategic decision to discontinue mRNA-0184 highlights a lack of alignment with Moderna's long-term investment priorities. The company is choosing to divest from this area to concentrate on its core competencies and more promising therapeutic avenues.
- Discontinuation Date: September 2024
- Therapeutic Area: Congestive Heart Failure
- BCG Matrix Classification: Dogs
- Strategic Rationale: Focus on core strengths and higher-growth opportunities.
Failed Ventures: The 'Dogs' in the Portfolio
Moderna's portfolio includes several candidates categorized as 'Dogs' in the BCG Matrix, reflecting discontinued or deprioritized projects with low market share and minimal growth potential. The Endemic Human Coronaviruses Vaccine (mRNA-1287) and KRAS Antigen-Specific Therapy (mRNA-5671) were both halted in September 2024, marking them as Dogs due to their failure to advance beyond early development or demonstrate sufficient promise.
Similarly, the oncology candidate mRNA-2752 and the congestive heart failure candidate mRNA-0184 were also moved to the Dogs quadrant after development ceased beyond Phase 1 trials by September 2024, signaling a strategic reallocation of resources to more promising ventures.
| Program | Status (as of Sept 2024) | BCG Category | Reason for Classification |
| mRNA-1287 (Endemic Coronaviruses) | Discontinued (Preclinical) | Dogs | Zero market share, low growth potential |
| mRNA-5671 (KRAS Therapy) | Development Halted (Phase 1) | Dogs | Low market share, low growth potential |
| mRNA-2752 (Oncology) | Deprioritized (Beyond Phase 1) | Dogs | Limited efficacy, low growth prospects |
| mRNA-0184 (Congestive Heart Failure) | Discontinued | Dogs | Zero market share, low growth potential |
Question Marks
Flu + COVID Combination Vaccine (mRNA-1083)
Moderna's mRNA-1083, a combination vaccine for influenza and COVID-19, is currently a question mark in the BCG matrix. It's in Phase 3 trials, showing promising results and aiming for regulatory approval. The market for such combination vaccines is expanding rapidly, driven by user convenience and the potential for higher vaccination rates.
While the market is attractive, mRNA-1083 has a negligible market share as it's not yet available commercially. This lack of current market presence, coupled with the substantial investment needed for its launch and widespread adoption, places it squarely in the question mark category. Its future success hinges on effective market penetration and competition.
Propionic Acidemia (PA) Therapeutic (mRNA-3927)
Moderna's mRNA-3927, an investigational therapy for Propionic Acidemia (PA), is currently in Phase 2 clinical trials. Early data indicates potential benefits for patients suffering from this rare metabolic disorder, suggesting it could become a valuable treatment option.
Propionic acidemia is a rare genetic condition, and the market for rare disease therapies is experiencing significant growth due to high unmet medical needs and the possibility of premium pricing. However, mRNA-3927 currently holds no market share, placing it in a position of high potential but also high risk within a new market segment.
The future success of mRNA-3927 is directly tied to the continuation of positive clinical trial outcomes and the ability to successfully navigate complex regulatory approval processes. This will necessitate significant and sustained financial investment from Moderna to bring this therapy to market and establish its presence.
Methylmalonic Acidemia (MMA) Therapeutic (mRNA-3705)
Moderna's mRNA-3705, targeting Methylmalonic Acidemia (MMA), is positioned as a question mark in the BCG matrix. Like its counterpart for Proprionic Acidemia (PA), this therapy is currently in Phase 2 trials and has been accepted into the FDA's START pilot program. A pivotal study is slated for the first half of 2025, indicating significant ongoing investment.
The MMA market represents a rare disease segment with considerable growth potential and a substantial unmet medical need. mRNA-3705 currently holds no market share, a defining characteristic of a question mark. The company's commitment to substantial investment in clinical development and navigating regulatory pathways is paramount for its potential future success.
Oncology Therapeutics (e.g., mRNA-4106, mRNA-4203)
Beyond mRNA-4157, Moderna is actively developing other oncology therapeutics, including mRNA-4106 and mRNA-4203, which fall into the question mark category of the BCG matrix. These represent high-growth potential areas within the oncology market. As of the latest available data, these programs are in early stages, with mRNA-4106 in Phase 1 trials and mRNA-4203 in preclinical or early Phase 1 development, indicating a low or non-existent current market share.
Significant research and development investment is essential for these candidates to demonstrate efficacy and safety, mirroring the characteristics of question marks. While their future success is not guaranteed, the substantial unmet need and projected growth in cancer therapies position them as strategic assets with the potential for high future returns. For instance, the global oncology drugs market was valued at approximately $200 billion in 2023 and is projected to grow substantially in the coming years, highlighting the attractive market dynamics for these early-stage assets.
- mRNA-4106 and mRNA-4203 are classified as question marks due to their early-stage development and low current market share in the high-growth oncology sector.
- These candidates require substantial R&D investment to validate their efficacy and safety profiles.
- The oncology market offers significant potential for high returns, making these strategic investments for future growth.
- Moderna’s investment in these early-stage programs reflects a long-term strategy to capture value in a rapidly evolving therapeutic landscape.
Latent Virus Vaccines (e.g., EBV, VZV)
Moderna's pipeline includes vaccine candidates targeting latent viruses like Epstein-Barr Virus (EBV) and Varicella-Zoster Virus (VZV), placing them in the question mark category of the BCG matrix. These are considered high-growth potential markets due to significant unmet needs or the prospect of superior vaccine technology.
While these markets offer substantial growth opportunities, Moderna's current market share for these specific latent virus vaccines is negligible, reflecting their early-stage development. For instance, the global vaccine market is projected to reach over $130 billion by 2030, indicating the scale of potential for successful latent virus vaccines.
- High Growth Potential: Markets for EBV and VZV vaccines are considered to have substantial growth prospects, driven by the prevalence of these infections and the desire for more effective preventative measures.
- Low Market Share: As these vaccine candidates are in Phase 2 trials, Moderna currently holds no commercial market share in these specific areas.
- Significant Investment Required: Advancing these programs through late-stage clinical trials, regulatory review, and eventual commercialization will necessitate considerable financial investment.
- Unmet Needs: Existing treatments or vaccines for latent viruses may have limitations, creating an opening for innovative solutions like those Moderna is developing.
Unlocking Growth: The Question Mark Pipeline
Moderna's question marks represent promising pipeline candidates with high growth potential but currently low market share. These assets, such as mRNA-1083 (influenza/COVID-19 combo vaccine) and investigational therapies for rare diseases like Propionic Acidemia (mRNA-3927) and Methylmalonic Acidemia (mRNA-3705), are in various stages of clinical development, often Phase 2 or 3 trials.
Significant investment is required to bring these question marks to market, with success dependent on positive clinical outcomes and regulatory approvals. The company's ventures into early-stage oncology therapeutics (mRNA-4106, mRNA-4203) and latent virus vaccines (EBV, VZV) also fall into this category, reflecting strategic bets on future market expansion. For example, the global oncology drugs market reached approximately $200 billion in 2023, underscoring the potential for these early-stage assets.
| Pipeline Asset | Therapeutic Area | BCG Category | Market Potential | Current Share | Development Stage |
| mRNA-1083 | Influenza/COVID-19 Vaccine | Question Mark | High (Convenience, Vaccination Rates) | Negligible | Phase 3 |
| mRNA-3927 | Propionic Acidemia | Question Mark | High (Rare Disease, Unmet Need) | None | Phase 2 |
| mRNA-3705 | Methylmalonic Acidemia | Question Mark | High (Rare Disease, Unmet Need) | None | Phase 2 (START Pilot Program) |
| mRNA-4106 | Oncology | Question Mark | High (Oncology Market Growth) | None | Phase 1 |
| mRNA-4203 | Oncology | Question Mark | High (Oncology Market Growth) | None | Preclinical/Early Phase 1 |
| Latent Virus Vaccines (EBV, VZV) | Infectious Disease | Question Mark | High (Unmet Need, Vaccine Tech) | Negligible | Phase 2 |
BCG Matrix Data Sources
Our BCG Matrix leverages robust data, including Moderna's financial filings, public health data, and market research on vaccine demand, to accurately assess product portfolio performance.
